Rocket Pharmaceuticals is trading 6.11% up in pre-market at $2.69 on October 8, after Goldman Sachs upgraded it from Sell to Neutral and raised its target from $3 to $4.
- Company-reported updated RP-A501 Danon data showed durable long-term activity and encouraging early safety observations in the modified Phase 2 trial.
- The supplied quote’s gain exceeded reports of a 2.8% pre-open move; broader futures were lower, not a clear explanation.
- Trading volume or activity level was unavailable in the supplied context or sources.